CoChat

Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index; 21 of the 30 sources its claims cite were checked for support.

Abstract

Metabolic dysfunction–associated steatotic liver disease (MASLD) is shaped by metabolic injury and tissue mechanics. This study investigated whether liver stiffening occurs early in MASLD and how extracellular matrix (ECM) mechanics interact with lipid droplet (LD) overload to promote inflammation, fibrogenesis, and lipid dysmetabolism. Clinical data, mouse models, and in vitro experiments are integrated. Liver stiffness shifted modestly with steatosis but increased substantially in the presence of inflammation. In a diet‐induced mouse model, liver stiffness increased before overt fibrosis. In cultured hepatocytes, stiff matrices combined with free fatty acid (FFA) induced steatosis synergistically amplified pro‐inflammatory and pro‐fibrotic signals, accompanied by cytoskeletal remodeling and nuclear deformation. YAP acted as a central mechanosensitive amplifier: stiffness drove YAP nuclear localization, and YAP knockdown blunted cytokine induction and fibrogenic gene expression under stiff + FFA conditions. Stiffness and LD overload jointly promoted lipogenesis and impaired lipophagy via YAP. Piezo1 is upregulated by stiff + FFA; its inhibition reduced Ca 2 ⁺ influx and prevented YAP activation. Collectively, early liver stiffening, together with LD‐derived intracellular stress, engages a Piezo1–YAP axis that amplifies inflammation, fibrogenesis, and disordered lipid metabolism, consistent with a proposed feed‐forward loop mechanism accelerating MASLD progression.

Overview

CoChat Summary

## TL;DR

This study argues that liver stiffness increases early in MASLD, before overt fibrosis, and that stiffness works with lipid droplet overload to drive inflammation, fibrogenesis, and disordered lipid metabolism. It identifies a Piezo1–YAP mechanotransduction axis in hepatocytes as the key pathway linking extracellular stiffness and intracellular lipid stress.

## Key findings

  • In a clinical cohort of 24,449 people, liver stiffness measurement (LSM) increased modestly with CAP-defined steatosis severity; in a second cohort of 1,315, people with elevated aminotransferases had higher CAP and LSM than enzyme-normal counterparts.
  • AFM on 5 surgical liver specimens showed graded increases in Young’s modulus from healthy liver to simple steatosis, steatohepatitis, and advanced fibrosis.
  • In an MCD-diet mouse model, liver stiffness increased with disease progression and rose before overt fibrosis; storage modulus correlated strongly with NAS, LD burden, AST/ALT, and circulating cytokines.
  • In hepatocyte models, stiff + FFA conditions most strongly increased inflammatory cytokines (IL-6, IL-1β, TNF-α), fibrogenic mediators (TGF-β1, IHH), YAP nuclear localization, lipogenesis, and impaired lipophagy; Piezo1 was the most strongly induced mechanosensitive channel and its inhibition reduced Ca²⁺ influx and YAP activation.

## Methods

  • Integrated two clinical cohorts, an MCD-diet mouse model, and in vitro hepatocyte experiments on tunable polyacrylamide hydrogels; clinical LSM/CAP were measured by FibroScan.
  • Compared soft (~0.5 kPa) versus stiff (~20 kPa) matrices, with or without FFA (OA:PA = 2:1, 0.5 mM), in HepG2 and THLE-2 cells.
  • Main analyses included AFM, rheometry, histology/IHC/IF, qRT-PCR, transcriptomic profiling, GSEA/GO/KEGG, correlation analyses, and YAP or Piezo1 perturbation (siRNA, GsMTx4).

## Limitations

  • The paper states that advanced fibrosis (F ≥ 3) could not be fully excluded in the clinical cohorts because there were no protocol liver biopsies.
  • It also states that the MCD diet lacks key features of human MASLD, such as obesity and insulin resistance.
  • The discussion notes that AFM-derived Young’s moduli are apparent comparative values, not absolute material properties, because the Hertz model assumes linear elasticity and homogeneity.
  • The text makes evident that the Piezo1 inhibitor GsMTx4 is not fully selective, so the specificity of Piezo1-mediated effects is not definitively proven by pharmacology alone.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/advs.202519109

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Hepatic tissue stiffening emerges early in MASLD progression and correlates with steatosis, inflammation, and fibrosis. (A) Schematic of study design. Two clinical cohorts (n = 24 449 and n = 1,315) underwent liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) assessment, with surgical specimens used for atomic force microscopy (AFM) analysis. (B) Heatmap showing the relationship between CAP‐defined steatosis grade (S0–S3) and LSM‐defined fibrosis stage (F0–F3). (C) Young's modulus of liver tissue measured by AFM in control, NAFL, MASH, and fibrosis patients. (D) Experimental timeline of the methionine‐ and choline‐deficient (MCD) diet mouse model (n = 7–12 per group). (E) Representative histological staining of mouse liver tissues: hematoxylin–eosin (H&E), Oil Red O, Masson's trichrome, and immunohistochemistry (IHC) for MMP2 and collagen I. Scale bars as indicated. (F) Quantification of AFM‐derived Young's modulus across groups. (G) Schematic of the rheometry setup used for oscillatory shear measurements of liver tissue. (H) Storage modulus measured by rheometry in control and MCD‐fed mice. (I) Correlation of storage modulus with MASLD activity score (NAS). (J) Correlation of storage modulus with LD percentage. (K,L) Quantification of MMP2 and collagen I expression by IHC. (M,N) Correlation of storage modulus with MMP2 and collagen I expression. (O–S) Correlations of storage modulus with serum biochemical and inflammatory markers, including AST (O), ALT (P), IL‐6 (Q), TNF‐α (R), and IL‐1β (S). Data are shown as mean ± SD. Statistical significance was determined by one‐way ANOVA with post hoc tests for multiple comparisons or Spearman's correlation for associations.
FIGURE 1 Hepatic tissue stiffening emerges early in MASLD progression and correlates with steatosis, inflammation, and fibrosis. (A) Schematic of study design. Two clinical cohorts (n = 24 449 and n = 1,315) underwent liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) assessment, with surgical specimens used for atomic force microscopy (AFM) analysis. (B) Heatmap showing the relationship between CAP‐defined steatosis grade (S0–S3) and LSM‐defined fibrosis stage (F0–F3). (C) Young's modulus of liver tissue measured by AFM in control, NAFL, MASH, and fibrosis patients. (D) Experimental timeline of the methionine‐ and choline‐deficient (MCD) diet mouse model (n = 7–12 per group). (E) Representative histological staining of mouse liver tissues: hematoxylin–eosin (H&E), Oil Red O, Masson's trichrome, and immunohistochemistry (IHC) for MMP2 and collagen I. Scale bars as indicated. (F) Quantification of AFM‐derived Young's modulus across groups. (G) Schematic of the rheometry setup used for oscillatory shear measurements of liver tissue. (H) Storage modulus measured by rheometry in control and MCD‐fed mice. (I) Correlation of storage modulus with MASLD activity score (NAS). (J) Correlation of storage modulus with LD percentage. (K,L) Quantification of MMP2 and collagen I expression by IHC. (M,N) Correlation of storage modulus with MMP2 and collagen I expression. (O–S) Correlations of storage modulus with serum biochemical and inflammatory markers, including AST (O), ALT (P), IL‐6 (Q), TNF‐α (R), and IL‐1β (S). Data are shown as mean ± SD. Statistical significance was determined by one‐way ANOVA with post hoc tests for multiple comparisons or Spearman's correlation for associations.CC BY · PubMed Central
FIGURE 2 ECM stiffness and lipid overload synergize to enhance pro‐inflammatory and pro‐fibrotic signaling in hepatocytes. (A) Schematic of polyacrylamide hydrogel system simulating soft (∼0.5 kPa) and stiff (∼20 kPa) liver matrices with or without FFA treatment (oleate: palmitate, 2:1; 0.5 mm, 24 h). (B) Representative images of HepG2 and THLE‐2 cells showing stiffness‐ and FFA‐dependent morphological changes. Scale bars, 100 µm. (C–E) ELISA quantification of secreted IL‐6, IL‐1β, and TNF‐α in HepG2 cells (n = 3 per group). (F–H) Transcript levels of IL‐6, IL‐1β, and TNF‐α in HepG2 cells (n = 3 per group). (I,J) Protein and transcript levels of TGF‐β1 in HepG2 cells (n = 3 per group). (K,L) Protein and transcript levels of IHH in HepG2 cells (n = 3 per group). (M) Immunohistochemistry of IHH in mouse livers at different disease stages (Control, NAFL, MASH, MASH+F). Scale bars, 100 µm. (N–P) Quantification of hepatic IHH score and serum IHH levels across disease stages (n = 7–12 per group). (O–Q) Correlation of storage modulus with hepatic IHH score and serum IHH concentration (Spearman's r, p <0.0001). (R) Working model: LD accumulation dominantly induces inflammatory cytokines (IL‐6, IL‐1β, TNF‐α), while matrix stiffness drives fibrogenic mediators (TGF‐β1, IHH). Together, these cues synergize to accelerate the transition from inflammation to fibrosis. Data are mean ± SD (n = 3 independent experiments). Statistical significance was determined by one‐way ANOVA with post hoc tests for multiple comparisons or Spearman's correlation for associations.
FIGURE 2 ECM stiffness and lipid overload synergize to enhance pro‐inflammatory and pro‐fibrotic signaling in hepatocytes. (A) Schematic of polyacrylamide hydrogel system simulating soft (∼0.5 kPa) and stiff (∼20 kPa) liver matrices with or without FFA treatment (oleate: palmitate, 2:1; 0.5 mm, 24 h). (B) Representative images of HepG2 and THLE‐2 cells showing stiffness‐ and FFA‐dependent morphological changes. Scale bars, 100 µm. (C–E) ELISA quantification of secreted IL‐6, IL‐1β, and TNF‐α in HepG2 cells (n = 3 per group). (F–H) Transcript levels of IL‐6, IL‐1β, and TNF‐α in HepG2 cells (n = 3 per group). (I,J) Protein and transcript levels of TGF‐β1 in HepG2 cells (n = 3 per group). (K,L) Protein and transcript levels of IHH in HepG2 cells (n = 3 per group). (M) Immunohistochemistry of IHH in mouse livers at different disease stages (Control, NAFL, MASH, MASH+F). Scale bars, 100 µm. (N–P) Quantification of hepatic IHH score and serum IHH levels across disease stages (n = 7–12 per group). (O–Q) Correlation of storage modulus with hepatic IHH score and serum IHH concentration (Spearman's r, p <0.0001). (R) Working model: LD accumulation dominantly induces inflammatory cytokines (IL‐6, IL‐1β, TNF‐α), while matrix stiffness drives fibrogenic mediators (TGF‐β1, IHH). Together, these cues synergize to accelerate the transition from inflammation to fibrosis. Data are mean ± SD (n = 3 independent experiments). Statistical significance was determined by one‐way ANOVA with post hoc tests for multiple comparisons or Spearman's correlation for associations.CC BY · PubMed Central
FIGURE 3 ECM stiffness synergizes with lipid overload to remodel hepatocyte cytoskeletal architecture and nuclear morphology. (A) Representative 3D reconstructions of HepG2 and THLE‐2 cells generated using Imaris software from confocal z‐stacks. Cells were cultured on soft (∼0.5 kPa) or stiff (∼20 kPa) collagen‐coated PA hydrogels, with or without FFA treatment (0.5 mm, oleate: palmitate 2:1). F‐actin filaments (phalloidin, red) and nuclei (DAPI, blue) were rendered in 3D. Filament tracing was performed to quantify actin fiber number, length, branching, and grid density, while nuclear geometry (volume, surface area, sphericity) was measured using the Imaris “Surface” module. Scale bars: 10 µm. (B,C) Quantification of apparent Young's modulus by AFM indentation in HepG2 (B) and THLE‐2 (C) cells under the indicated conditions. (D,E) Radar plots showing normalized microfilament architecture parameters, including filament length, number, branching, and grid density, in HepG2 (D) and THLE‐2 (E) cells. All parameters were normalized to the soft condition (= 1). (F,G) Immunofluorescence images of nuclear morphology (Lamin A/C, green) and LD accumulation (BODIPY 493/503, green) in HepG2 (F) and THLE‐2 (G) cells. Nuclei were counterstained with DAPI (blue). Scale bars: 10 µm. (H, I) Quantitative analysis of nuclear geometry in HepG2 (H) and THLE‐2 (I) cells, including sphericity, volume, and surface area, normalized to Soft = 1. Statistical significance was calculated relative to the soft group and is indicated by asterisks on the plots. Absence of asterisks denotes no significant difference. (J) Schematic summary of structural remodeling induced by ECM stiffness and FFA. Stiffness promotes cytoskeletal reorganization (increased fiber number/length, reduced branching), while LD accumulation exerts perinuclear compression. Combined stiff + FFA conditions result in pronounced actin alignment, nuclear deformation, and LD accumulation. Data are mean ± SD (n = 3 independent biological replicates). Statistical significance was determined by one‐way ANOVA followed by Tukey's post hoc test. * p <0.05, ** p <0.01, ***p <0.001, **** p <0.0001; ns, not significant.
FIGURE 3 ECM stiffness synergizes with lipid overload to remodel hepatocyte cytoskeletal architecture and nuclear morphology. (A) Representative 3D reconstructions of HepG2 and THLE‐2 cells generated using Imaris software from confocal z‐stacks. Cells were cultured on soft (∼0.5 kPa) or stiff (∼20 kPa) collagen‐coated PA hydrogels, with or without FFA treatment (0.5 mm, oleate: palmitate 2:1). F‐actin filaments (phalloidin, red) and nuclei (DAPI, blue) were rendered in 3D. Filament tracing was performed to quantify actin fiber number, length, branching, and grid density, while nuclear geometry (volume, surface area, sphericity) was measured using the Imaris “Surface” module. Scale bars: 10 µm. (B,C) Quantification of apparent Young's modulus by AFM indentation in HepG2 (B) and THLE‐2 (C) cells under the indicated conditions. (D,E) Radar plots showing normalized microfilament architecture parameters, including filament length, number, branching, and grid density, in HepG2 (D) and THLE‐2 (E) cells. All parameters were normalized to the soft condition (= 1). (F,G) Immunofluorescence images of nuclear morphology (Lamin A/C, green) and LD accumulation (BODIPY 493/503, green) in HepG2 (F) and THLE‐2 (G) cells. Nuclei were counterstained with DAPI (blue). Scale bars: 10 µm. (H, I) Quantitative analysis of nuclear geometry in HepG2 (H) and THLE‐2 (I) cells, including sphericity, volume, and surface area, normalized to Soft = 1. Statistical significance was calculated relative to the soft group and is indicated by asterisks on the plots. Absence of asterisks denotes no significant difference. (J) Schematic summary of structural remodeling induced by ECM stiffness and FFA. Stiffness promotes cytoskeletal reorganization (increased fiber number/length, reduced branching), while LD accumulation exerts perinuclear compression. Combined stiff + FFA conditions result in pronounced actin alignment, nuclear deformation, and LD accumulation. Data are mean ± SD (n = 3 independent biological replicates). Statistical significance was determined by one‐way ANOVA followed by Tukey's post hoc test. * p <0.05, ** p <0.01, ***p <0.001, **** p <0.0001; ns, not significant.CC BY · PubMed Central
FIGURE 4 YAP mediates ECM stiffness‐ and lipid overload‐induced pro‐inflammatory and pro‐fibrotic transcriptional programs. (A) Volcano plot showing differential gene expression in HepG2 cells cultured on stiff hydrogels with FFA (stiff + FFA) versus soft hydrogels with FFA (soft + FFA). Classical YAP target genes (e.g., AMOTL2, CCN2, CCND1, TEAD1, EDN1, ANKRD1) were significantly upregulated in the stiff + FFA condition. Thresholds: |log2FC| > 1 and FDR <0.05. (B) GO/KEGG enrichment analysis based on the stiff + FFA versus soft + FFA comparison showing significant enrichment of pathways related to cytoskeletal organization, ECM–receptor interaction, and Hippo/YAP signaling. (C) GSEA further confirmed significant activation of the Hippo/YAP signaling pathway under stiff + FFA relative to soft + FFA conditions. (D) IHC staining of YAP in mouse liver tissues from control, Steatosis, MASH, and fibrotic MASH (MASH+F) groups. Scale bars: 50 µm. (E,F) Quantification of YAP IHC scores (E) and percentage of YAP nuclear‐positive hepatocytes (F) across mouse groups. (G,H) Correlations between YAP IHC scores (G) or percentage of YAP nuclear‐positive cells (H) and liver storage modulus in mouse liver tissues. (I–K) Immunofluorescence showing YAP localization in HepG2 cells. On soft hydrogels, YAP remains cytoplasmic (even with LD accumulation), whereas stiffness drives YAP nuclear translocation, further enhanced by FFA treatment. (J) Quantification of YAP fluorescence intensity; (K) Nucleus‐to‐cytoplasm (N/C) fluorescence ratio. Scale bars: 5 µm. (L) qPCR analysis of YAP1 mRNA levels under the indicated conditions. (M–N) siRNA knockdown of YAP reduced YAP nuclear accumulation and fluorescence intensity. Scale bars: 5 µm. (O–Y) Functional readouts of YAP activity. (P–R) Cytokine secretion (IL‐6, IL‐1β, TNF‐α) by ELISA under stiff + FFA versus controls, showing YAP‐dependent induction. (S,T) Fibrogenic mediators (TGF‐β1, IHH) measured by ELISA, predominantly stiffness‐driven but still YAP‐dependent. (U–Y) qPCR confirming corresponding changes in cytokine and fibrogenic gene expression. (Z) Schematic model: ECM stiffness promotes YAP nuclear translocation, activating pro‐fibrotic transcriptional programs; lipid overload recruits YAP as a transcriptional co‐activator, amplifying inflammatory signaling. Together, these synergistic inputs reinforce inflammation and fibrosis, accelerating MASLD progression. Data are mean ± SD (n = 3 independent biological replicates). Statistical significance was determined by one‐way ANOVA with Tukey's post hoc test or Spearman's correlation.
FIGURE 4 YAP mediates ECM stiffness‐ and lipid overload‐induced pro‐inflammatory and pro‐fibrotic transcriptional programs. (A) Volcano plot showing differential gene expression in HepG2 cells cultured on stiff hydrogels with FFA (stiff + FFA) versus soft hydrogels with FFA (soft + FFA). Classical YAP target genes (e.g., AMOTL2, CCN2, CCND1, TEAD1, EDN1, ANKRD1) were significantly upregulated in the stiff + FFA condition. Thresholds: |log2FC| > 1 and FDR <0.05. (B) GO/KEGG enrichment analysis based on the stiff + FFA versus soft + FFA comparison showing significant enrichment of pathways related to cytoskeletal organization, ECM–receptor interaction, and Hippo/YAP signaling. (C) GSEA further confirmed significant activation of the Hippo/YAP signaling pathway under stiff + FFA relative to soft + FFA conditions. (D) IHC staining of YAP in mouse liver tissues from control, Steatosis, MASH, and fibrotic MASH (MASH+F) groups. Scale bars: 50 µm. (E,F) Quantification of YAP IHC scores (E) and percentage of YAP nuclear‐positive hepatocytes (F) across mouse groups. (G,H) Correlations between YAP IHC scores (G) or percentage of YAP nuclear‐positive cells (H) and liver storage modulus in mouse liver tissues. (I–K) Immunofluorescence showing YAP localization in HepG2 cells. On soft hydrogels, YAP remains cytoplasmic (even with LD accumulation), whereas stiffness drives YAP nuclear translocation, further enhanced by FFA treatment. (J) Quantification of YAP fluorescence intensity; (K) Nucleus‐to‐cytoplasm (N/C) fluorescence ratio. Scale bars: 5 µm. (L) qPCR analysis of YAP1 mRNA levels under the indicated conditions. (M–N) siRNA knockdown of YAP reduced YAP nuclear accumulation and fluorescence intensity. Scale bars: 5 µm. (O–Y) Functional readouts of YAP activity. (P–R) Cytokine secretion (IL‐6, IL‐1β, TNF‐α) by ELISA under stiff + FFA versus controls, showing YAP‐dependent induction. (S,T) Fibrogenic mediators (TGF‐β1, IHH) measured by ELISA, predominantly stiffness‐driven but still YAP‐dependent. (U–Y) qPCR confirming corresponding changes in cytokine and fibrogenic gene expression. (Z) Schematic model: ECM stiffness promotes YAP nuclear translocation, activating pro‐fibrotic transcriptional programs; lipid overload recruits YAP as a transcriptional co‐activator, amplifying inflammatory signaling. Together, these synergistic inputs reinforce inflammation and fibrosis, accelerating MASLD progression. Data are mean ± SD (n = 3 independent biological replicates). Statistical significance was determined by one‐way ANOVA with Tukey's post hoc test or Spearman's correlation.CC BY · PubMed Central
FIGURE 5 YAP links matrix stiffness to lipogenic reprogramming and suppression of lipolysis. (A) GO pathway enrichment analysis comparing stiff + FFA versus soft + FFA conditions in HepG2 cells. Stiff ECM combined with FFA loading significantly enriched pathways related to fatty acid biosynthesis, fatty acid metabolism, and fatty acid degradation, while also highlighting enrichment of negative regulation of macroautophagy, indicating coordinated activation of lipogenic programs and suppression of autophagic processes. (B) GSEA enrichment plot for the fatty acid degradation pathway based on the transcriptomic ranking of stiff + FFA versus soft + FFA conditions (NES = −1.551, p <0.001, FDR q = 0.204), showing a relative downregulation of fatty acid degradation under stiff mechanical cues combined with FFA exposure. (C) Schematic model illustrating how ECM stiffness and FFA cooperate through YAP to regulate LDs, upregulating lipogenesis (e.g., SREBP1) while repressing lipolysis (e.g., PNPLA2). (D,E) Representative immunofluorescence (IF) images of HepG2 and THLE‐2 cells showing LDs (BODIPY 493/503, green), F‐actin (phalloidin, red), and nuclei (DAPI, blue) under soft + FFA and stiff + FFA. Quantification of BODIPY fluorescence intensity shows significantly increased LD accumulation under stiff + FFA. Scale bars: 5 µm. (F,G) Representative IF images of HepG2 cells transfected with si‐NC or si‐YAP under stiff + FFA, showing reduced LD accumulation upon YAP knockdown. Scale bars: 10 µm. (H–J) IF staining of SREBP1 (red), BODIPY 493/503 (green), and DAPI (blue). YAP knockdown reduces SREBP1 nuclear accumulation under stiff conditions with or without FFA. Quantifications show fluorescence intensity (I) and N/C ratio (J). Scale bars: 10 µm. (K–M) IHC staining of SREBP1 in mouse liver tissues from control, steatosis, MASH, and fibrotic MASH (MASH+F). Quantification shows progressive increase of SREBP1 nuclear positivity (L) correlating with storage modulus (M, rheometry). Scale bars: 50 µm. (N,O) IF staining of PNPLA2 (red), BODIPY 493/503 (green), and DAPI (blue) in HepG2 cells. YAP knockdown restores PNPLA2 expression under stiff + FFA. Scale bars: 10 µm. (P–R) IHC staining of PNPLA2 in mouse liver tissues. PNPLA2 expression decreases with disease progression and negatively correlates with storage modulus. Scale bars: 50 µm. Data are mean ± SD (n = 3 independent biological replicates). Statistical significance was determined by one‐way ANOVA with Tukey's post hoc test or Spearman's correlation.
FIGURE 5 YAP links matrix stiffness to lipogenic reprogramming and suppression of lipolysis. (A) GO pathway enrichment analysis comparing stiff + FFA versus soft + FFA conditions in HepG2 cells. Stiff ECM combined with FFA loading significantly enriched pathways related to fatty acid biosynthesis, fatty acid metabolism, and fatty acid degradation, while also highlighting enrichment of negative regulation of macroautophagy, indicating coordinated activation of lipogenic programs and suppression of autophagic processes. (B) GSEA enrichment plot for the fatty acid degradation pathway based on the transcriptomic ranking of stiff + FFA versus soft + FFA conditions (NES = −1.551, p <0.001, FDR q = 0.204), showing a relative downregulation of fatty acid degradation under stiff mechanical cues combined with FFA exposure. (C) Schematic model illustrating how ECM stiffness and FFA cooperate through YAP to regulate LDs, upregulating lipogenesis (e.g., SREBP1) while repressing lipolysis (e.g., PNPLA2). (D,E) Representative immunofluorescence (IF) images of HepG2 and THLE‐2 cells showing LDs (BODIPY 493/503, green), F‐actin (phalloidin, red), and nuclei (DAPI, blue) under soft + FFA and stiff + FFA. Quantification of BODIPY fluorescence intensity shows significantly increased LD accumulation under stiff + FFA. Scale bars: 5 µm. (F,G) Representative IF images of HepG2 cells transfected with si‐NC or si‐YAP under stiff + FFA, showing reduced LD accumulation upon YAP knockdown. Scale bars: 10 µm. (H–J) IF staining of SREBP1 (red), BODIPY 493/503 (green), and DAPI (blue). YAP knockdown reduces SREBP1 nuclear accumulation under stiff conditions with or without FFA. Quantifications show fluorescence intensity (I) and N/C ratio (J). Scale bars: 10 µm. (K–M) IHC staining of SREBP1 in mouse liver tissues from control, steatosis, MASH, and fibrotic MASH (MASH+F). Quantification shows progressive increase of SREBP1 nuclear positivity (L) correlating with storage modulus (M, rheometry). Scale bars: 50 µm. (N,O) IF staining of PNPLA2 (red), BODIPY 493/503 (green), and DAPI (blue) in HepG2 cells. YAP knockdown restores PNPLA2 expression under stiff + FFA. Scale bars: 10 µm. (P–R) IHC staining of PNPLA2 in mouse liver tissues. PNPLA2 expression decreases with disease progression and negatively correlates with storage modulus. Scale bars: 50 µm. Data are mean ± SD (n = 3 independent biological replicates). Statistical significance was determined by one‐way ANOVA with Tukey's post hoc test or Spearman's correlation.CC BY · PubMed Central
FIGURE 6 YAP mediates stiffness‐induced impairment of lipophagy. (A) Representative immunofluorescence (IF) images of HepG2 cells showing p62 (red), LDs (BODIPY 493/503, green), and nuclei (DAPI, blue) under Soft, soft + FFA, Stiff, and stiff + FFA conditions. Scale bars: 10 µm. (B) Quantification of p62 fluorescence intensity in HepG2 cells under the indicated conditions. (C) Colocalization coefficient of p62 puncta with BODIPY‐stained LDs under the indicated conditions. (D,E) qRT‐PCR analysis of p62/SQSTM1 (D) and LC3B (E) mRNA expression under the indicated conditions. (F) qRT‐PCR analysis of core autophagy regulators (mTOR, TFEB, ATG7, ATG5, LAMP2, CTSD), showing no significant differences between soft + FFA and stiff + FFA. (G) Representative IF images of p62 (red) in mouse liver tissues from control, steatosis, MASH, and fibrotic MASH (MASH+F) groups. Nuclei are stained with DAPI (blue). Scale bars: 50 µm. (H) Quantification of p62 fluorescence intensity in mouse liver sections. (I,J) Correlations between hepatic p62 intensity and storage modulus (I), and between p62 intensity and LD burden (J). (K,L) Western blot analysis of LC3‐II and LC3‐I in mouse liver tissues, with quantification of the LC3‐II/LC3‐I ratio (L). GAPDH served as loading control. (M) Representative IF images of HepG2 cells showing p62 (red), BODIPY 493/503 (green), and nuclei (blue) under Stiff and stiff + FFA conditions with siNC or siYAP. Scale bars: 10 µm. (N–P) Quantification of p62 fluorescence intensity (N), p62 mRNA expression (O), and selected autophagy regulators (mTOR, TFEB, ATG7, ATG5, LAMP2, CTSD) (P) in HepG2 cells with YAP knockdown. Data are mean ± SD (n = 3 independent biological replicates). Statistical significance was determined by one‐way ANOVA with post hoc tests for multiple comparisons or Spearman's correlation for associations.
FIGURE 6 YAP mediates stiffness‐induced impairment of lipophagy. (A) Representative immunofluorescence (IF) images of HepG2 cells showing p62 (red), LDs (BODIPY 493/503, green), and nuclei (DAPI, blue) under Soft, soft + FFA, Stiff, and stiff + FFA conditions. Scale bars: 10 µm. (B) Quantification of p62 fluorescence intensity in HepG2 cells under the indicated conditions. (C) Colocalization coefficient of p62 puncta with BODIPY‐stained LDs under the indicated conditions. (D,E) qRT‐PCR analysis of p62/SQSTM1 (D) and LC3B (E) mRNA expression under the indicated conditions. (F) qRT‐PCR analysis of core autophagy regulators (mTOR, TFEB, ATG7, ATG5, LAMP2, CTSD), showing no significant differences between soft + FFA and stiff + FFA. (G) Representative IF images of p62 (red) in mouse liver tissues from control, steatosis, MASH, and fibrotic MASH (MASH+F) groups. Nuclei are stained with DAPI (blue). Scale bars: 50 µm. (H) Quantification of p62 fluorescence intensity in mouse liver sections. (I,J) Correlations between hepatic p62 intensity and storage modulus (I), and between p62 intensity and LD burden (J). (K,L) Western blot analysis of LC3‐II and LC3‐I in mouse liver tissues, with quantification of the LC3‐II/LC3‐I ratio (L). GAPDH served as loading control. (M) Representative IF images of HepG2 cells showing p62 (red), BODIPY 493/503 (green), and nuclei (blue) under Stiff and stiff + FFA conditions with siNC or siYAP. Scale bars: 10 µm. (N–P) Quantification of p62 fluorescence intensity (N), p62 mRNA expression (O), and selected autophagy regulators (mTOR, TFEB, ATG7, ATG5, LAMP2, CTSD) (P) in HepG2 cells with YAP knockdown. Data are mean ± SD (n = 3 independent biological replicates). Statistical significance was determined by one‐way ANOVA with post hoc tests for multiple comparisons or Spearman's correlation for associations.CC BY · PubMed Central
FIGURE 7 Piezo1 is an upstream mechanosensor orchestrating hepatocyte responses to stiffness. (A) Heatmap showing transcriptomic profiling of mechanosensitive ion channels under stiff + FFA versus soft + FFA conditions. Piezo1 was the most robustly induced, whereas other candidates (ASIC1, TRPC1, KCNK4) exhibited minimal changes. (B) Schematic diagram illustrating Piezo1 as an upstream mechanosensitive Ca2⁺ channel that links extracellular matrix stiffness to YAP‐dependent transcriptional programs. (C) Representative immunohistochemistry (IHC) staining of Piezo1 in mouse livers from control, steatosis, MASH, and fibrotic MASH (MASH+F). Scale bars: 100 µm. (D) Quantification of Piezo1 IHC score showing progressive upregulation from control and steatosis to MASH and MASH+F. (E) Correlation analysis between Piezo1 IHC score and hepatic storage modulus, showing a strong positive association (r = 0.8143, p <0.0001). (F) Representative immunofluorescence (IF) images of Piezo1 (red) and nuclei (DAPI, blue) in HepG2 cells cultured under Soft, soft + FFA, Stiff, and stiff + FFA conditions. Piezo1 exhibits a punctate or clustered distribution under stiff conditions. Scale bars: 10 µm. (G,H) Quantification of Piezo1 fluorescence intensity (G) and Ca2⁺ influx measured by Fluo‐4 AM staining (green, H) under the indicated conditions. Scale bars: 40 µm (Ca2⁺). (I) qRT‐PCR analysis of PIEZO1 mRNA expression in HepG2 cells under the indicated conditions. (J–M) Pharmacological inhibition of Piezo1 with GsMTx4 under Stiff and stiff + FFA conditions. IF images show Piezo1 (red, J), Ca2⁺ influx (green, J), and actin cytoskeleton remodeling (phalloidin, K). Quantification of Piezo1 fluorescence (L), Ca2⁺ influx (M), and PIEZO1 mRNA expression (N). (O–R) Effect of Piezo1 inhibition on YAP activity. IF images of YAP (red) and nuclei (blue) under the indicated conditions (P). Quantification of YAP fluorescence intensity (O), nuclear/cytoplasmic ratio of YAP (Q), and YAP1 mRNA expression (R). Scale bars: 10 µm. Data are mean ± SD (n = 3 independent biological replicates). Statistical significance was determined by one‐way ANOVA with Tukey's post hoc test or Spearman's correlation.
FIGURE 7 Piezo1 is an upstream mechanosensor orchestrating hepatocyte responses to stiffness. (A) Heatmap showing transcriptomic profiling of mechanosensitive ion channels under stiff + FFA versus soft + FFA conditions. Piezo1 was the most robustly induced, whereas other candidates (ASIC1, TRPC1, KCNK4) exhibited minimal changes. (B) Schematic diagram illustrating Piezo1 as an upstream mechanosensitive Ca2⁺ channel that links extracellular matrix stiffness to YAP‐dependent transcriptional programs. (C) Representative immunohistochemistry (IHC) staining of Piezo1 in mouse livers from control, steatosis, MASH, and fibrotic MASH (MASH+F). Scale bars: 100 µm. (D) Quantification of Piezo1 IHC score showing progressive upregulation from control and steatosis to MASH and MASH+F. (E) Correlation analysis between Piezo1 IHC score and hepatic storage modulus, showing a strong positive association (r = 0.8143, p <0.0001). (F) Representative immunofluorescence (IF) images of Piezo1 (red) and nuclei (DAPI, blue) in HepG2 cells cultured under Soft, soft + FFA, Stiff, and stiff + FFA conditions. Piezo1 exhibits a punctate or clustered distribution under stiff conditions. Scale bars: 10 µm. (G,H) Quantification of Piezo1 fluorescence intensity (G) and Ca2⁺ influx measured by Fluo‐4 AM staining (green, H) under the indicated conditions. Scale bars: 40 µm (Ca2⁺). (I) qRT‐PCR analysis of PIEZO1 mRNA expression in HepG2 cells under the indicated conditions. (J–M) Pharmacological inhibition of Piezo1 with GsMTx4 under Stiff and stiff + FFA conditions. IF images show Piezo1 (red, J), Ca2⁺ influx (green, J), and actin cytoskeleton remodeling (phalloidin, K). Quantification of Piezo1 fluorescence (L), Ca2⁺ influx (M), and PIEZO1 mRNA expression (N). (O–R) Effect of Piezo1 inhibition on YAP activity. IF images of YAP (red) and nuclei (blue) under the indicated conditions (P). Quantification of YAP fluorescence intensity (O), nuclear/cytoplasmic ratio of YAP (Q), and YAP1 mRNA expression (R). Scale bars: 10 µm. Data are mean ± SD (n = 3 independent biological replicates). Statistical significance was determined by one‐way ANOVA with Tukey's post hoc test or Spearman's correlation.CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 2 Not valid · 2 Not checked · 133 Own results and interpretations

69 more claims

Create a free account to see all 148 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 57
  • Probably not a substantial claim. 22
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Research works printed but not linked: 1

  1. I. L. Ivanovska, M. P. Tobin, T. Bai, L. J. Dooling, and D. E. Discher, “ Small Lipid Droplets Are Rigid Enough to Indent a Nucleus, Dilute the Lamina, and Cause Rupture,” Journal of Cell Biology 222, no. 8 (2023): 202208123, 10.1083/jcb.202208123. PMC10202833 37212777 · doi:10.1083/jcb.202208123

Cited by

See all 14

Metadata

Authors
Ma, J., Xie, N., Wang, Z., Liang, X., Han, Y., Zhao, Q., Wang, M., Lu, H., Kou, W., Alazawi, W., Wang, J., Li, L., Liu, N., Liu, N., Shi, H., & Xu, F.
Affiliations
  • Second Affiliated Hospital of Xi'an Jiaotong University (CN)
  • Nanjing University of Aeronautics and Astronautics (CN)
  • Xi'an Jiaotong University (CN)
  • Queen Mary University of London (GB)
  • Department of Gastrointestinal Surgery Hainan General Hospital Hainan Affiliated Hospital of Hainan Medical University Haikou P. R. China
  • Department of Gastroenterology Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University) Haikou P. R. China
Corresponding author
  • Shi, Haitao
  • Xu, Feng
Venue
Advanced Science
Publisher
Wiley
Published
2026-01-04
Volume
13
Issue
19
Pages
e19109-e19109
ISSN
2198-3844 (ISSN-L)
OpenAlex
W7118166457
Cited by
14
References
43
Citations by year
2026: 14
FWCI
48.44
Type
journal article
Language
en
Open access
Licence
Locations
  • Advanced Science (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (12432015,82560549)
  • Key Research and Development Projects of Shaanxi Province (2023GXLH‐033)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
non-alcoholic fatty liver disease, liver stiffness, mechanotransduction, Piezo1, YAP, extracellular matrix mechanics, liver inflammation, liver fibrosis
MeSH terms
YAP-Signaling Proteins, Animals, Disease Models, Animal, Fatty Liver, Humans, Inflammation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction. https://app.cochat.ai/papers/10.1002/advs.202519109
The paper
Ma, J., Xie, N., Wang, Z., Liang, X., Han, Y., Zhao, Q., Wang, M., Lu, H., Kou, W., Alazawi, W., Wang, J., Li, L., Liu, N., Liu, N., Shi, H., & Xu, F. (2026). Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction. Advanced Science. https://doi.org/10.1002/advs.202519109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.